Characteristics of patients reporting use of antidepressant drugs (N06A) or opioid consumption (N02A) at last follow-up
| Parameters | No use of antidepressants or opioids | Opioid consumption | Use of antidepressants |
| n | 1227 | 44* | 45* |
| No of medicines per patient, (incl. DMARD) | 2.2 (2.0) | 5.8 (1.8) | 5.1 (2.4) |
| Age, years | 23.0 (4.0) | 25.0 (5.3) | 23.7 (4.8) |
| Female, N (%) | 827 (67.4) | 32 (72.7) | 36 (80.0) |
| Disease duration, years | 13.4 (5.9) | 17.9 (7.3) | 15.6 (7.4) |
| Patient-reported disease activity (NRS 0–10) | 2.7 (2.2) | 5.5 (1.9) | 4.5 (2.1) |
| Patient-reported pain (NRS 0–10) | 2.5 (2.3) | 5.5 (2.0) | 4.5 (2.5) |
| Patient-reported fatigue (NRS 0–10) | 3.0 (2.7) | 6.2 (2.3) | 5.5 (2.4) |
| HAQ total score (range 0–3) | 0.25 (0.47) | 1.2 (0.76) | 0.72 (0.78) |
| Patient-reported HRQoL, SF-36, mental component summary score | 49.7 (9.4) | 45.9 (11.1) | 39.9 (10.9) |
| Patient-reported HRQoL, SF-36, physical component summary score | 47.6 (10.3) | 31.0 (9.9) | 36.7 (11.4) |
| Time from symptom onset to first bDMARD in years | 5.3 (4.3) | 7.3 (5.1) | 7.4 (4.9) |
| Current treatment with DMARD, N (%) | 774 (63.1) | 36 (81.8) | 35 (77.8) |
| Current treatment with synthetic DMARDs, N (%) | 369 (30.1) | 32 (52.3) | 20 (44.4) |
| Current treatment with biological DMARD, N (%) | 696 (56.8) | 31 (70.6) | 31 (68.8) |
| NSAIDs, N (%) | 566 (46.1) | 35 (79.5) | 31 (68.9) |
| Systemic glucocorticoids, N (%) | 216 (17.6) | 24 (54.5) | 16 (35.6) |
The values are Mean (SD) unless indicated otherwise.
*Ten patients were taking both antidepressants and opioids, contributing to both columns.
DMARD, disease modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; HRQoL, health-related quality of life; NRS, Numerical Rating Scale; NSAIDS, non-steroidal anti-inflammatory drugs; SF-36, Short Form-36.